Partnership will leverage Facet’s proprietary bioprinting know-how and Novo Nordisk’s experience and know-how in stem cell differentiation and cell remedy improvement and manufacturing.

Facet to obtain 75 million US {dollars} in preliminary funds and as much as 650 million {dollars} in future milestone funds per product arising from the collaboration, plus tiered royalties. 

Vancouver, BC, Canada and Bagsværd, Denmark, 12 April 2023 – Facet Biosystems and Novo Nordisk A/S as we speak introduced a collaboration, improvement, and licence settlement to develop bioprinted tissue therapeutics designed to switch, restore, or complement organic features contained in the physique with the goal of delivering a brand new class of really disease-modifying remedies for diabetes and weight problems.  

The collaboration will leverage Facet’s proprietary bioprinting know-how and Novo Nordisk’s experience and know-how in stem cell differentiation and cell remedy improvement and manufacturing. 

Below the phrases of the settlement, Novo Nordisk will obtain an unique, worldwide licence to make use of Facet’s bioprinting know-how to develop as much as 4 merchandise for the therapy of diabetes and/or weight problems. Facet will obtain preliminary funds of 75 million US {dollars}, together with an upfront cost, analysis funding and an funding within the type of a convertible notice. Facet can be eligible to obtain as much as 650 million {dollars} in future improvement, regulatory, business and gross sales milestone funds per product, in addition to tiered royalties on future product gross sales. 

“We’re thrilled to associate with Novo Nordisk, a world chief and pioneer within the struggle towards diabetes and continual ailments, to create breakthrough therapeutics that would rework the lives of thousands and thousands of individuals world wide,” mentioned Tamer Mohamed, chief govt officer, Facet Biosystems. “This partnership leverages Facet’s full-stack tissue therapeutic platform, gifted staff and daring imaginative and prescient, and reinforces our technique to create bioprinted tissue therapeutics by partnerships with international business leaders whereas additionally advancing our inside therapeutic pipeline.”

Facet has developed a platform know-how which will enable for improvement of a novel class of cell-based drugs designed to be biologically useful, encapsulated to be immune-protective, and appropriate for surgical implantation. Novo Nordisk has developed experience to distinguish stem cells into a wide selection of cells that could be used to switch broken and misplaced cells which might result in a particular illness, reminiscent of insulin-producing beta cells in sort 1 diabetes, in addition to manufacturing capabilities to provide the cells at scale. 

By combining the strongholds of every firm, the purpose of the collaboration is to develop implantable bioprinted tissues to switch, restore or complement organic features. These tissues will probably be designed to be allogeneic, which means the cells used are derived from a single supply to extend the viability of future large-scale manufacturing.

“Novo Nordisk has constructed robust capabilities relating to producing useful and extremely pure therapeutic substitute cells on the highest high quality and at scale,” mentioned Jacob Sten Petersen, company vice chairman and head of Cell Remedy R&D, Novo Nordisk. “Collaborating with Facet Biosystems provides an necessary part to our technique to develop complete cell remedy merchandise. We’re excited to co-develop options for cell remedy supply that would result in life-changing remedies for these residing with a severe continual illness.”

The collaboration will initially give attention to creating bioprinted tissue therapeutics designed to keep up regular blood glucose ranges with out the necessity for immunosuppression, which can symbolize a transformative therapy for individuals residing with sort 1 diabetes. 

Facet Biosystems is a biotechnology firm pioneering the event of bioprinted tissue therapeutics to remodel how we deal with presently incurable ailments. Facet is creating these subsequent technology cell therapies by making use of its full-stack tissue therapeutic platform, which mixes the corporate’s proprietary bioprinting know-how, therapeutic cells, biomaterials, and computational design. Facet’s bioprinted tissue therapeutics are designed to switch, restore, or complement organic perform contained in the physique with the goal of treating presently incurable ailments reminiscent of sort 1 diabetes in addition to genetic and purchased liver ailments. Study extra at www.aspectbiosystems.com. 

Novo Nordisk is a number one international healthcare firm, based in 1923 and headquartered in Denmark. Our objective is to drive change to defeat diabetes and different severe continual ailments reminiscent of weight problems and uncommon blood and endocrine issues. We accomplish that by pioneering scientific breakthroughs, increasing entry to our medicines, and dealing to forestall and in the end remedy illness. Novo Nordisk employs about 54,400 individuals in 80 nations and markets its merchandise in round 170 nations. For extra info, go to novonordisk.com, Fb,  Twitter,  LinkedIn and YouTube.

Contact for additional info